首页 > 最新文献

Breast Cancer Research and Treatment最新文献

英文 中文
Identifying research priorities for improving information and support for patients undergoing breast cancer surgery: a UK patient-centred priority setting project. 确定研究重点,改善为乳腺癌手术患者提供的信息和支持:英国一项以患者为中心的优先事项确定项目。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-06-24 DOI: 10.1007/s10549-024-07413-8
Emma Johnston, Katherine Cowan, Mairead MacKenzie, Sonia Patton, Lesley Turner, Patricia Fairbrother, Stuart A McIntosh, Shelley Potter

Purpose: To use robust consensus methods with individuals with lived breast cancer experience to agree the top 10 research priorities to improve information and support for patients undergoing breast cancer surgery in the UK.

Methods: Research uncertainties related to information and support for breast cancer surgery submitted by patients and carers were analysed thematically to generate summary questions for inclusion in an online Delphi survey. Individuals with lived breast cancer experience completed two Delphi rounds including feedback in which they selected their top 10 research priorities from the list provided. The most highly ranked priorities from the survey were discussed at an in-person prioritisation workshop at which the final top 10 was agreed.

Results: The 543 uncertainties submitted by 156 patients/carers were categorised into 63 summary questions for inclusion in the Delphi survey. Of the 237 individuals completing Round 1, 190 (80.2%) participated in Round 2. The top 25 survey questions were carried forward for discussion at the in-person prioritisation workshop at which 17 participants from across the UK agreed the final top 10 research priorities. Key themes included ensuring patients were fully informed about all treatment options and given balanced, tailored information to support informed decision-making and empower their recovery. Equity of access to treatments including contralateral mastectomy for symmetry was also considered a research priority.

Conclusion: This process has identified the top 10 research priorities to improve information and support for patients undergoing breast cancer surgery. Work is now needed to develop studies to address these important questions.

目的:采用稳健的共识方法,与有乳腺癌生活经验的个人共同商定十大研究重点,以改善英国乳腺癌手术患者的信息和支持:方法: 对患者和护理人员提交的与乳腺癌手术信息和支持相关的研究不确定性进行专题分析,以生成摘要问题,并将其纳入在线德尔菲调查。有乳腺癌生活经验的个人完成了两轮德尔菲调查,其中包括反馈意见,他们从提供的清单中选出了他们认为最重要的 10 个研究重点。调查中排名最靠前的优先事项在现场优先事项研讨会上进行了讨论,并就最终的 10 大优先事项达成了一致意见:156 名患者/护理人员提交的 543 个不确定因素被归类为 63 个摘要问题,以纳入德尔菲调查。在完成第一轮调查的 237 人中,有 190 人(80.2%)参加了第二轮调查。来自英国各地的 17 名参与者在此次研讨会上商定了最终的 10 大研究重点。关键主题包括:确保患者充分了解所有治疗方案,并为其提供均衡、有针对性的信息,以支持其做出知情决策,增强其康复能力。公平获得包括对侧乳房对称性切除术在内的治疗也被视为研究重点:这一过程确定了十大研究重点,以改善为乳腺癌手术患者提供的信息和支持。现在需要针对这些重要问题开展研究。
{"title":"Identifying research priorities for improving information and support for patients undergoing breast cancer surgery: a UK patient-centred priority setting project.","authors":"Emma Johnston, Katherine Cowan, Mairead MacKenzie, Sonia Patton, Lesley Turner, Patricia Fairbrother, Stuart A McIntosh, Shelley Potter","doi":"10.1007/s10549-024-07413-8","DOIUrl":"10.1007/s10549-024-07413-8","url":null,"abstract":"<p><strong>Purpose: </strong>To use robust consensus methods with individuals with lived breast cancer experience to agree the top 10 research priorities to improve information and support for patients undergoing breast cancer surgery in the UK.</p><p><strong>Methods: </strong>Research uncertainties related to information and support for breast cancer surgery submitted by patients and carers were analysed thematically to generate summary questions for inclusion in an online Delphi survey. Individuals with lived breast cancer experience completed two Delphi rounds including feedback in which they selected their top 10 research priorities from the list provided. The most highly ranked priorities from the survey were discussed at an in-person prioritisation workshop at which the final top 10 was agreed.</p><p><strong>Results: </strong>The 543 uncertainties submitted by 156 patients/carers were categorised into 63 summary questions for inclusion in the Delphi survey. Of the 237 individuals completing Round 1, 190 (80.2%) participated in Round 2. The top 25 survey questions were carried forward for discussion at the in-person prioritisation workshop at which 17 participants from across the UK agreed the final top 10 research priorities. Key themes included ensuring patients were fully informed about all treatment options and given balanced, tailored information to support informed decision-making and empower their recovery. Equity of access to treatments including contralateral mastectomy for symmetry was also considered a research priority.</p><p><strong>Conclusion: </strong>This process has identified the top 10 research priorities to improve information and support for patients undergoing breast cancer surgery. Work is now needed to develop studies to address these important questions.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"215-222"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting. 在现实环境中,激素受体阳性、人类表皮生长因子受体-2阴性转移性乳腺癌患者一线与二线CDK 4/6抑制剂的使用对比。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-06-26 DOI: 10.1007/s10549-024-07415-6
Gretchen Kimmick, Asal Pilehvari, Wen You, Gloribel Bonilla, Roger Anderson

Purpose: To compare CDK4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) in the first- versus second-line setting for treatment of hormone receptor positive (HR+), HER2 negative, metastatic breast cancer (MBC) using real-world evidence.

Methods: Patients with HR+, HER2 negative MBC, diagnosed between 2/3/2015 and 11/2/2021 and having ≥ 3 months follow-up were identified from the nationwide electronic health record-derived Flatiron Health de-identified database. Treatment cohorts included: (1) first-line ET with a CDK 4/6i (1st-line CDK4/6i) versus (2) first-line ET alone followed by second-line ET with a CDK4/6i (2nd-line CDK4/6i). Differences in baseline characteristics were tested using chi-square tests and two-sample t-tests. Time to third-line therapy, time to start of chemotherapy, and overall survival were compared using Kaplan-Maier method.

Results: The analysis included 2771 patients (2170 1st-line CDK4/6i and 601 2nd-line CDK4/6i). Patients receiving 1st-line CDK4/6i were younger (75% vs 68% < 75 years old, p = 0.0001), less likely uninsured or not having insurance status documented (10% vs. 13%, p = 0.04), of better performance status (50% vs 43% with ECOG 0, p = 0.03), and more likely to have de novo MBC (36% vs. 24%, p < 0.001). Time to third-line therapy (49 vs 22 months, p < 0.001) and time to chemotherapy (68 vs 41 months, p < 0.001) were longer in those receiving first-line CDK4/6i. Overall survival (54 vs 49 months, p = 0.33) was similar between groups.

Conclusion: Use of CDK4/6i with first-, vs second-, line ET was associated with longer time to receipt of 3rd-line therapy and longer time to receipt of chemotherapy.

目的:利用真实世界的证据,比较CDK4/6抑制剂(CDK4/6i)与内分泌疗法(ET)在激素受体阳性(HR+)、HER2阴性转移性乳腺癌(MBC)治疗中的一线与二线疗程:从全国范围内的电子健康记录衍生的 Flatiron Health 去标识数据库中识别出 HR+、HER2 阴性 MBC 患者,这些患者在 2015 年 3 月 2 日至 2021 年 2 月 11 日期间确诊,且随访时间≥ 3 个月。治疗队列包括(1) 使用 CDK 4/6i 的一线 ET(一线 CDK4/6i)与 (2) 单用一线 ET 后使用 CDK4/6i 的二线 ET(二线 CDK4/6i)。基线特征差异采用卡方检验和双样本t检验。采用Kaplan-Maier法比较了三线治疗时间、化疗开始时间和总生存期:分析包括2771名患者(2170名一线CDK4/6i患者和601名二线CDK4/6i患者)。接受一线CDK4/6i治疗的患者更年轻(75%对68%):CDK4/6i与一线ET和二线ET相比,与接受三线治疗的时间更长和接受化疗的时间更长有关。
{"title":"First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting.","authors":"Gretchen Kimmick, Asal Pilehvari, Wen You, Gloribel Bonilla, Roger Anderson","doi":"10.1007/s10549-024-07415-6","DOIUrl":"10.1007/s10549-024-07415-6","url":null,"abstract":"<p><strong>Purpose: </strong>To compare CDK4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) in the first- versus second-line setting for treatment of hormone receptor positive (HR+), HER2 negative, metastatic breast cancer (MBC) using real-world evidence.</p><p><strong>Methods: </strong>Patients with HR+, HER2 negative MBC, diagnosed between 2/3/2015 and 11/2/2021 and having ≥ 3 months follow-up were identified from the nationwide electronic health record-derived Flatiron Health de-identified database. Treatment cohorts included: (1) first-line ET with a CDK 4/6i (1st-line CDK4/6i) versus (2) first-line ET alone followed by second-line ET with a CDK4/6i (2nd-line CDK4/6i). Differences in baseline characteristics were tested using chi-square tests and two-sample t-tests. Time to third-line therapy, time to start of chemotherapy, and overall survival were compared using Kaplan-Maier method.</p><p><strong>Results: </strong>The analysis included 2771 patients (2170 1st-line CDK4/6i and 601 2nd-line CDK4/6i). Patients receiving 1st-line CDK4/6i were younger (75% vs 68% < 75 years old, p = 0.0001), less likely uninsured or not having insurance status documented (10% vs. 13%, p = 0.04), of better performance status (50% vs 43% with ECOG 0, p = 0.03), and more likely to have de novo MBC (36% vs. 24%, p < 0.001). Time to third-line therapy (49 vs 22 months, p < 0.001) and time to chemotherapy (68 vs 41 months, p < 0.001) were longer in those receiving first-line CDK4/6i. Overall survival (54 vs 49 months, p = 0.33) was similar between groups.</p><p><strong>Conclusion: </strong>Use of CDK4/6i with first-, vs second-, line ET was associated with longer time to receipt of 3rd-line therapy and longer time to receipt of chemotherapy.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"263-273"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11455668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141449727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A prospective study of vitamin D, proinflammatory cytokines, and risk of fragility fractures in women on aromatase inhibitors for breast cancer. 一项关于服用芳香化酶抑制剂治疗乳腺癌的女性体内维生素 D、促炎细胞因子和脆性骨折风险的前瞻性研究。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-08 DOI: 10.1007/s10549-024-07423-6
Emily Liang, Michael Beshara, Haiyang Sheng, Xin-Wei Huang, Janise M Roh, Cecile A Laurent, Catherine Lee, Jennifer Delmerico, Li Tang, Joan C Lo, Chi-Chen Hong, Christine B Ambrosone, Lawrence H Kushi, Marilyn L Kwan, Song Yao

Background: Vitamin D is critical to bone health by regulating intestinal absorption of calcium, whereas proinflammatory cytokines, including IL-1, IL-6, IL-12, and TNF-α, are known to increase bone resorption. We hypothesized that vitamin D and these cytokines at the time of breast cancer diagnosis were predictive for fragility fractures in women receiving aromatase inhibitors (AIs).

Methods: In a prospective cohort of 1,709 breast cancer patients treated with AIs, we measured the levels of 25-hydroxyvitamin D (25OHD), IL-1β, IL-6, IL-12, and TNF-α from baseline blood samples. The associations of these biomarkers were analyzed with bone turnover markers (BALP and TRACP), bone regulatory markers (OPG and RANKL), bone mineral density (BMD) close to cancer diagnosis, and risk of fragility fractures during a median of 7.5 years of follow up.

Results: Compared to patients with vitamin D deficiency, patients with sufficient levels had higher bone turnover, lower BMD, and higher fracture risk; the latter became non-significant after controlling for covariates including BMD and no longer existed when patients taking vitamin D supplement or bisphosphonates or with history of fracture or osteoporosis were excluded. There was a non-significant trend of higher levels of IL-1β and TNF-α associated with higher risk of fracture (highest vs. lowest tertile, IL-1β: adjusted HR=1.37, 95% CI=0.94-1.99; TNF-α: adjusted HR=1.38, 95% CI=0.96-1.98).

Conclusions: Our results do not support proinflammatory cytokines or vitamin D levels as predictors for risk of fragility fractures in women receiving AIs for breast cancer.

背景:维生素 D 可调节肠道对钙的吸收,对骨骼健康至关重要,而包括 IL-1、IL-6、IL-12 和 TNF-α 在内的促炎细胞因子可增加骨吸收。我们假设,乳腺癌确诊时的维生素 D 和这些细胞因子可预测接受芳香化酶抑制剂(AIs)治疗的妇女是否会发生脆性骨折:方法: 我们对接受芳香化酶抑制剂治疗的 1,709 名乳腺癌患者进行了前瞻性队列研究,测量了基线血样中 25- 羟维生素 D (25OHD)、IL-1β、IL-6、IL-12 和 TNF-α 的水平。在中位 7.5 年的随访期间,分析了这些生物标志物与骨转换标志物(BALP 和 TRACP)、骨调节标志物(OPG 和 RANKL)、接近癌症诊断时的骨矿物质密度(BMD)以及脆性骨折风险之间的关联:与维生素D缺乏症患者相比,维生素D水平充足的患者骨质流失率更高、骨密度更低,骨折风险更高;在控制了包括骨密度在内的协变量后,后者变得不显著,而在排除服用维生素D补充剂或双磷酸盐类药物或有骨折或骨质疏松症病史的患者后,后者不再存在。IL-1β和TNF-α水平越高,骨折风险越高,但这一趋势并不显著(最高与最低三等分位数,IL-1β:调整后HR=1.37,95% CI=0.94-1.99;TNF-α:调整后HR=1.38,95% CI=0.96-1.98):我们的研究结果不支持将促炎细胞因子或维生素 D 水平作为预测乳腺癌患者脆性骨折风险的指标。
{"title":"A prospective study of vitamin D, proinflammatory cytokines, and risk of fragility fractures in women on aromatase inhibitors for breast cancer.","authors":"Emily Liang, Michael Beshara, Haiyang Sheng, Xin-Wei Huang, Janise M Roh, Cecile A Laurent, Catherine Lee, Jennifer Delmerico, Li Tang, Joan C Lo, Chi-Chen Hong, Christine B Ambrosone, Lawrence H Kushi, Marilyn L Kwan, Song Yao","doi":"10.1007/s10549-024-07423-6","DOIUrl":"10.1007/s10549-024-07423-6","url":null,"abstract":"<p><strong>Background: </strong>Vitamin D is critical to bone health by regulating intestinal absorption of calcium, whereas proinflammatory cytokines, including IL-1, IL-6, IL-12, and TNF-α, are known to increase bone resorption. We hypothesized that vitamin D and these cytokines at the time of breast cancer diagnosis were predictive for fragility fractures in women receiving aromatase inhibitors (AIs).</p><p><strong>Methods: </strong>In a prospective cohort of 1,709 breast cancer patients treated with AIs, we measured the levels of 25-hydroxyvitamin D (25OHD), IL-1β, IL-6, IL-12, and TNF-α from baseline blood samples. The associations of these biomarkers were analyzed with bone turnover markers (BALP and TRACP), bone regulatory markers (OPG and RANKL), bone mineral density (BMD) close to cancer diagnosis, and risk of fragility fractures during a median of 7.5 years of follow up.</p><p><strong>Results: </strong>Compared to patients with vitamin D deficiency, patients with sufficient levels had higher bone turnover, lower BMD, and higher fracture risk; the latter became non-significant after controlling for covariates including BMD and no longer existed when patients taking vitamin D supplement or bisphosphonates or with history of fracture or osteoporosis were excluded. There was a non-significant trend of higher levels of IL-1β and TNF-α associated with higher risk of fracture (highest vs. lowest tertile, IL-1β: adjusted HR=1.37, 95% CI=0.94-1.99; TNF-α: adjusted HR=1.38, 95% CI=0.96-1.98).</p><p><strong>Conclusions: </strong>Our results do not support proinflammatory cytokines or vitamin D levels as predictors for risk of fragility fractures in women receiving AIs for breast cancer.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"349-358"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The heterogeneity of breast cancer metastasis: a bioinformatics analysis utilizing single-cell RNA sequencing data. 乳腺癌转移的异质性:利用单细胞 RNA 测序数据进行的生物信息学分析。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-11 DOI: 10.1007/s10549-024-07428-1
Ardo Sanjaya, Hana Ratnawati, Oeij Anindita Adhika, Faiz Rizqy Rahmatilah

Purpose: Breast cancer is a common malignancy in women, and its metastasis is a leading cause of cancer-related deaths. Single-cell RNA sequencing (scRNA-seq) can distinguish the molecular characteristics of metastasis and identify predictor genes for patient prognosis. This article explores gene expression in primary breast cancer tumor tissue against metastatic cells in the lymph node and liver using scRNA-seq.

Methods: Breast cancer scRNA-seq data from the Gene Expression Omnibus were used. The data were processed using R and the Seurat package. The cells were clustered and identified using Metascape. InferCNV is used to analyze the variation in copy number. Differential expression analysis was conducted for the cancer cells using Seurat and was enriched using Metascape.

Results: We identified 18 distinct cell clusters, 6 of which were epithelial. CNV analysis identified significant alterations with duplication of chromosomes 1, 8, and 19. Differential gene analysis resulted in 17 upregulated and 171 downregulated genes for the primary tumor in the primary tumor vs. liver metastasis comparison and 43 upregulated and 4 downregulated genes in the primary tumor in the primary tumor vs lymph node metastasis comparison. Several enriched terms include Ribosome biogenesis, NTP synthesis, Epithelial dedifferentiation, Autophagy, and genes associated with epithelial-to-mesenchymal transitions.

Conclusion: No single gene or pathway can clearly explain the mechanisms behind tumor metastasis. Several mechanisms contribute to lymph node and liver metastasis, such as the loss of differentiation, epithelial-to-mesenchymal transition, and autophagy. These findings necessitate further study of metastatic tissue for effective drug development.

目的:乳腺癌是女性常见的恶性肿瘤,其转移是癌症相关死亡的主要原因。单细胞 RNA 测序(scRNA-seq)可区分转移的分子特征,并确定预测患者预后的基因。本文利用 scRNA-seq 技术探讨了原发性乳腺癌肿瘤组织与淋巴结和肝脏中转移细胞的基因表达:方法:使用基因表达总库(Gene Expression Omnibus)中的乳腺癌 scRNA-seq 数据。使用 R 和 Seurat 软件包处理数据。使用 Metascape 对细胞进行聚类和识别。InferCNV 用于分析拷贝数的变化。使用 Seurat 对癌细胞进行差异表达分析,并使用 Metascape 进行富集:我们发现了 18 个不同的细胞群,其中 6 个是上皮细胞。CNV分析发现了1、8和19号染色体重复的重大改变。差异基因分析结果显示,在原发肿瘤与肝转移比较中,原发肿瘤有17个基因上调,171个基因下调;在原发肿瘤与淋巴结转移比较中,原发肿瘤有43个基因上调,4个基因下调。一些富集的术语包括核糖体生物发生、NTP合成、上皮细胞去分化、自噬以及与上皮细胞向间质转化相关的基因:结论:没有一种单一的基因或途径可以清楚地解释肿瘤转移背后的机制。导致淋巴结和肝转移的机制有多种,如分化丧失、上皮向间质转化和自噬。这些发现表明有必要进一步研究转移组织,以开发有效的药物。
{"title":"The heterogeneity of breast cancer metastasis: a bioinformatics analysis utilizing single-cell RNA sequencing data.","authors":"Ardo Sanjaya, Hana Ratnawati, Oeij Anindita Adhika, Faiz Rizqy Rahmatilah","doi":"10.1007/s10549-024-07428-1","DOIUrl":"10.1007/s10549-024-07428-1","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is a common malignancy in women, and its metastasis is a leading cause of cancer-related deaths. Single-cell RNA sequencing (scRNA-seq) can distinguish the molecular characteristics of metastasis and identify predictor genes for patient prognosis. This article explores gene expression in primary breast cancer tumor tissue against metastatic cells in the lymph node and liver using scRNA-seq.</p><p><strong>Methods: </strong>Breast cancer scRNA-seq data from the Gene Expression Omnibus were used. The data were processed using R and the Seurat package. The cells were clustered and identified using Metascape. InferCNV is used to analyze the variation in copy number. Differential expression analysis was conducted for the cancer cells using Seurat and was enriched using Metascape.</p><p><strong>Results: </strong>We identified 18 distinct cell clusters, 6 of which were epithelial. CNV analysis identified significant alterations with duplication of chromosomes 1, 8, and 19. Differential gene analysis resulted in 17 upregulated and 171 downregulated genes for the primary tumor in the primary tumor vs. liver metastasis comparison and 43 upregulated and 4 downregulated genes in the primary tumor in the primary tumor vs lymph node metastasis comparison. Several enriched terms include Ribosome biogenesis, NTP synthesis, Epithelial dedifferentiation, Autophagy, and genes associated with epithelial-to-mesenchymal transitions.</p><p><strong>Conclusion: </strong>No single gene or pathway can clearly explain the mechanisms behind tumor metastasis. Several mechanisms contribute to lymph node and liver metastasis, such as the loss of differentiation, epithelial-to-mesenchymal transition, and autophagy. These findings necessitate further study of metastatic tissue for effective drug development.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"379-390"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term outcome of invasive pure micropapillary breast cancer compared with invasive mixed micropapillary and invasive ductal breast cancer: a matched retrospective study. 浸润性纯微乳头状乳腺癌与浸润性混合微乳头状乳腺癌和浸润性导管乳腺癌的长期预后比较:一项配对回顾性研究。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-04 DOI: 10.1007/s10549-024-07422-7
Francesca Magnoni, Beatrice Bianchi, Eleonora Pagan, Giovanni Corso, Isabella Sala, Vincenzo Bagnardi, Sangalli Claudia, Roberta Brancaccio, Elisa Bottazzoli, Antony Boato, Elisabetta Munzone, Silvia Dellapasqua, Nicola Fusco, Galimberti Viviana, Paolo Veronesi

Purpose: Data on the prognostic impact of the micropapillary component in breast cancer are limited. The purpose of this study was to investigate the clinicopathological characteristics and long-term outcomes of pure and mixed invasive micropapillary breast cancer (IMPC) patients compared to invasive ductal cancer (IDC) patients.

Methods: This retrospective study analysed all IMPC and IDC patients treated at the European Institute of Oncology (IEO) between 1997 and 2019. The overall cohort of IMPC patients was divided in two groups, pure and mixed IMPC. Each patient with mixed or pure IMPC was matched with one patient with IDC, based on year of surgery, age, pT, pN, and molecular subtype.

Results: A total of 30,115 IDC, 120 pure IMPC and 150 mixed IMPC patients were considered eligible. Compared to IDC, pure and mixed IMPC patients presented a higher rate of locally advanced disease (pT2-T3, pN2-N3), vascular invasion, and Luminal B subtype. After matching, pure and mixed IMPC showed a significant higher rate of vascular invasion compared to IDC patients (p < 0.001). Invasive disease-free survival was better in IDC compared to pure IMPC patients (p = 0.11). Long-term overall survival was significantly worse in pure IMPC group compared to IDC group (p = 0.004), being instead similar between mixed IMPC vs matched IDC (p = 0.07).

Conclusion: These real-world data reported the worse prognosis of pure IMPC compared to IDC, highlighting the peculiar prognostic value of the micropapillary subtype itself in the decision-making process of IMPC management. An accurate pre-surgical diagnostic evaluation and a multidisciplinary approach are pivotal to best personalize its treatment.

目的:有关乳腺癌微乳头状瘤对预后影响的数据十分有限。本研究旨在调查纯性和混合性浸润性微乳头状乳腺癌(IMPC)患者与浸润性导管癌(IDC)患者相比的临床病理特征和长期预后:这项回顾性研究分析了1997年至2019年期间在欧洲肿瘤研究所(IEO)接受治疗的所有IMPC和IDC患者。IMPC患者总体分为两组,即纯IMPC和混合IMPC。根据手术年份、年龄、pT、pN和分子亚型,将每位混合型或纯合型IMPC患者与一位IDC患者配对:共有 30 115 名 IDC 患者、120 名纯 IMPC 患者和 150 名混合 IMPC 患者符合条件。与IDC相比,纯IMPC和混合IMPC患者的局部晚期疾病(pT2-T3、pN2-N3)、血管侵犯和Luminal B亚型的比例更高。匹配后,与 IDC 患者相比,纯 IMPC 和混合 IMPC 患者的血管侵犯率明显更高(p 结论:纯 IMPC 和混合 IMPC 患者的血管侵犯率明显高于 IDC 患者:这些真实世界的数据显示,纯IMPC的预后比IDC差,突出了微乳头亚型本身在IMPC治疗决策过程中的特殊预后价值。准确的术前诊断评估和多学科方法对个性化治疗至关重要。
{"title":"Long-term outcome of invasive pure micropapillary breast cancer compared with invasive mixed micropapillary and invasive ductal breast cancer: a matched retrospective study.","authors":"Francesca Magnoni, Beatrice Bianchi, Eleonora Pagan, Giovanni Corso, Isabella Sala, Vincenzo Bagnardi, Sangalli Claudia, Roberta Brancaccio, Elisa Bottazzoli, Antony Boato, Elisabetta Munzone, Silvia Dellapasqua, Nicola Fusco, Galimberti Viviana, Paolo Veronesi","doi":"10.1007/s10549-024-07422-7","DOIUrl":"10.1007/s10549-024-07422-7","url":null,"abstract":"<p><strong>Purpose: </strong>Data on the prognostic impact of the micropapillary component in breast cancer are limited. The purpose of this study was to investigate the clinicopathological characteristics and long-term outcomes of pure and mixed invasive micropapillary breast cancer (IMPC) patients compared to invasive ductal cancer (IDC) patients.</p><p><strong>Methods: </strong>This retrospective study analysed all IMPC and IDC patients treated at the European Institute of Oncology (IEO) between 1997 and 2019. The overall cohort of IMPC patients was divided in two groups, pure and mixed IMPC. Each patient with mixed or pure IMPC was matched with one patient with IDC, based on year of surgery, age, pT, pN, and molecular subtype.</p><p><strong>Results: </strong>A total of 30,115 IDC, 120 pure IMPC and 150 mixed IMPC patients were considered eligible. Compared to IDC, pure and mixed IMPC patients presented a higher rate of locally advanced disease (pT2-T3, pN2-N3), vascular invasion, and Luminal B subtype. After matching, pure and mixed IMPC showed a significant higher rate of vascular invasion compared to IDC patients (p < 0.001). Invasive disease-free survival was better in IDC compared to pure IMPC patients (p = 0.11). Long-term overall survival was significantly worse in pure IMPC group compared to IDC group (p = 0.004), being instead similar between mixed IMPC vs matched IDC (p = 0.07).</p><p><strong>Conclusion: </strong>These real-world data reported the worse prognosis of pure IMPC compared to IDC, highlighting the peculiar prognostic value of the micropapillary subtype itself in the decision-making process of IMPC management. An accurate pre-surgical diagnostic evaluation and a multidisciplinary approach are pivotal to best personalize its treatment.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"333-347"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-reported observations on medical procedure timeliness (PROMPT) in breast cancer: a qualitative study. 关于乳腺癌医疗程序及时性的患者报告观察(PROMPT):一项定性研究。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-04 DOI: 10.1007/s10549-024-07406-7
Marie L Fefferman, Tammy K Stump, Danielle Thompson, Sandra Simovic, Riley J Medenwald, Katharine Yao

Purpose: Timeliness of care is an important healthcare outcome measure. The objective of this study was to explore patient perspectives on the timeliness of breast cancer diagnosis and treatment at accredited breast cancer centers.

Methods: In this qualitative study, 1 hour virtual interviews were conducted with participants 18-75 years old who were diagnosed and treated for stage 0-III breast cancer at a National Accreditation Program for Breast Centers facility from 2018 to 2022. Thematic analysis was used to identify key themes of participant experiences.

Results: Twenty-eight participants were interviewed. Two thematic domains were identified: etiologies of expedited or delayed care and the impact of delayed or expedited care on patients. Within these domains, multiple themes emerged. For etiologies of expedited or delayed care, participants discussed (1) the effect of scheduling appointments, (2) the COVID-19 pandemic, (3) dissatisfaction with the timeline for various parts of the diagnostic workup, and (4) delays related to patient factors, including socioeconomic status. For the impact of expedited or delayed care, patients discussed (1) the emotional and mental impact of waiting, (2) the importance of communication and clear expectations, and (3) the impact of electronic health portals. Patients desired each care interval (e.g., the time from mammogram to breast biopsy) to be approximately 7 days, with longer intervals sometimes preferred prior to surgery.

Conclusion: These patient interviews identify areas of delay and provide patient-centered, actionable items to improve the timeliness of breast cancer care.

目的:治疗的及时性是衡量医疗效果的一个重要指标。本研究旨在探讨患者对认可乳腺癌中心乳腺癌诊断和治疗及时性的看法:在这项定性研究中,我们对 2018 年至 2022 年期间在国家乳腺中心认证计划机构接受 0-III 期乳腺癌诊断和治疗的 18-75 岁参与者进行了 1 小时的虚拟访谈。采用主题分析法确定参与者经历的关键主题:28 名参与者接受了访谈。确定了两个主题领域:加速或延迟治疗的病因以及延迟或加速治疗对患者的影响。在这些领域中,出现了多个主题。在加速或延迟治疗的病因方面,参与者讨论了(1)预约时间的影响,(2)COVID-19 大流行,(3)对诊断工作各部分的时间安排不满意,以及(4)与患者因素(包括社会经济地位)有关的延迟。关于加速或延迟护理的影响,患者讨论了(1)等待对情绪和精神的影响,(2)沟通和明确期望的重要性,以及(3)电子健康门户网站的影响。患者希望每次治疗间隔时间(如从乳房 X 光检查到乳房活检的时间)为 7 天左右,有时希望手术前的间隔时间更长:这些患者访谈确定了延误的领域,并提供了以患者为中心的可操作项目,以改善乳腺癌护理的及时性。
{"title":"Patient-reported observations on medical procedure timeliness (PROMPT) in breast cancer: a qualitative study.","authors":"Marie L Fefferman, Tammy K Stump, Danielle Thompson, Sandra Simovic, Riley J Medenwald, Katharine Yao","doi":"10.1007/s10549-024-07406-7","DOIUrl":"10.1007/s10549-024-07406-7","url":null,"abstract":"<p><strong>Purpose: </strong>Timeliness of care is an important healthcare outcome measure. The objective of this study was to explore patient perspectives on the timeliness of breast cancer diagnosis and treatment at accredited breast cancer centers.</p><p><strong>Methods: </strong>In this qualitative study, 1 hour virtual interviews were conducted with participants 18-75 years old who were diagnosed and treated for stage 0-III breast cancer at a National Accreditation Program for Breast Centers facility from 2018 to 2022. Thematic analysis was used to identify key themes of participant experiences.</p><p><strong>Results: </strong>Twenty-eight participants were interviewed. Two thematic domains were identified: etiologies of expedited or delayed care and the impact of delayed or expedited care on patients. Within these domains, multiple themes emerged. For etiologies of expedited or delayed care, participants discussed (1) the effect of scheduling appointments, (2) the COVID-19 pandemic, (3) dissatisfaction with the timeline for various parts of the diagnostic workup, and (4) delays related to patient factors, including socioeconomic status. For the impact of expedited or delayed care, patients discussed (1) the emotional and mental impact of waiting, (2) the importance of communication and clear expectations, and (3) the impact of electronic health portals. Patients desired each care interval (e.g., the time from mammogram to breast biopsy) to be approximately 7 days, with longer intervals sometimes preferred prior to surgery.</p><p><strong>Conclusion: </strong>These patient interviews identify areas of delay and provide patient-centered, actionable items to improve the timeliness of breast cancer care.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"123-132"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resistance to FOXM1 inhibitors in breast cancer is accompanied by impeding ferroptosis and apoptotic cell death. 乳腺癌对 FOXM1 抑制剂的抗药性伴随着铁凋亡和细胞凋亡的阻碍。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-09 DOI: 10.1007/s10549-024-07420-9
Sandeep Kumar, Yvonne Ziegler, Blake N Plotner, Kristen M Flatt, Sung Hoon Kim, John A Katzenellenbogen, Benita S Katzenellenbogen

Purpose: Cancer treatments often become ineffective because of acquired drug resistance. To characterize changes in breast cancer cells accompanying development of resistance to inhibitors of the oncogenic transcription factor, FOXM1, we investigated the suppression of cell death pathways, especially ferroptosis, in FOXM1 inhibitor-resistant cells. We also explored whether ferroptosis activators can synergize with FOXM1 inhibitors and can overcome FOXM1 inhibitor resistance.

Methods: In estrogen receptor-positive and triple-negative breast cancer cells treated with FOXM1 inhibitor NB73 and ferroptosis activators dihydroartemisinin and JKE1674, alone and in combination, we measured suppression of cell viability, motility, and colony formation, and monitored changes in gene and protein pathway expressions and mitochondrial integrity.

Results: Growth suppression of breast cancer cells by FOXM1 inhibitors is accompanied by increased cell death and alterations in mitochondrial morphology and metabolic activity. Low doses of FOXM1 inhibitor strongly synergize with ferroptosis inducers to reduce cell viability, migration, colony formation, and expression of proliferation-related genes, and increase intracellular Fe+2 and lipid peroxidation, markers of ferroptosis. Acquired resistance to FOXM1 inhibition is associated with increased expression of cancer stem-cell markers and proteins that repress ferroptosis, enabling cell survival and drug resistance. Notably, resistant cells are still sensitive to growth suppression by low doses of ferroptosis activators, effectively overcoming the acquired resistance.

Conclusion: Delineating changes in viability and cell death pathways that can overcome drug resistance should be helpful in determining approaches that might best prevent or reverse resistance to therapeutic targeting of FOXM1 and ultimately improve patient clinical outcomes.

目的:癌症治疗通常会因获得性耐药性而失效。为了描述乳腺癌细胞对致癌转录因子 FOXM1 抑制剂产生耐药性后的变化特征,我们研究了 FOXM1 抑制剂耐药细胞中细胞死亡通路,尤其是铁突变的抑制作用。我们还探讨了铁突变激活剂是否能与 FOXM1 抑制剂协同作用并克服 FOXM1 抑制剂耐药性:方法:在雌激素受体阳性和三阴性乳腺癌细胞中,单独或联合使用 FOXM1 抑制剂 NB73 和铁蛋白激活剂双氢青蒿素和 JKE1674,我们测量了细胞活力、运动性和集落形成的抑制作用,并监测了基因和蛋白通路表达的变化以及线粒体的完整性:结果:FOXM1 抑制剂对乳腺癌细胞生长的抑制作用伴随着细胞死亡的增加以及线粒体形态和代谢活性的改变。低剂量的 FOXM1 抑制剂与铁变态反应诱导剂有很强的协同作用,可降低细胞活力、迁移、集落形成和增殖相关基因的表达,并增加细胞内铁+2 和脂质过氧化反应(铁变态反应的标志物)。对 FOXM1 抑制的获得性耐药性与癌症干细胞标志物和抑制铁变态反应的蛋白质表达增加有关,从而使细胞得以存活并产生耐药性。值得注意的是,耐药细胞对低剂量铁突变激活剂的生长抑制仍然敏感,从而有效克服了获得性耐药性:结论:阐明能克服耐药性的存活率和细胞死亡途径的变化,有助于确定能最好地预防或逆转 FOXM1 靶向治疗耐药性的方法,并最终改善患者的临床疗效。
{"title":"Resistance to FOXM1 inhibitors in breast cancer is accompanied by impeding ferroptosis and apoptotic cell death.","authors":"Sandeep Kumar, Yvonne Ziegler, Blake N Plotner, Kristen M Flatt, Sung Hoon Kim, John A Katzenellenbogen, Benita S Katzenellenbogen","doi":"10.1007/s10549-024-07420-9","DOIUrl":"10.1007/s10549-024-07420-9","url":null,"abstract":"<p><strong>Purpose: </strong>Cancer treatments often become ineffective because of acquired drug resistance. To characterize changes in breast cancer cells accompanying development of resistance to inhibitors of the oncogenic transcription factor, FOXM1, we investigated the suppression of cell death pathways, especially ferroptosis, in FOXM1 inhibitor-resistant cells. We also explored whether ferroptosis activators can synergize with FOXM1 inhibitors and can overcome FOXM1 inhibitor resistance.</p><p><strong>Methods: </strong>In estrogen receptor-positive and triple-negative breast cancer cells treated with FOXM1 inhibitor NB73 and ferroptosis activators dihydroartemisinin and JKE1674, alone and in combination, we measured suppression of cell viability, motility, and colony formation, and monitored changes in gene and protein pathway expressions and mitochondrial integrity.</p><p><strong>Results: </strong>Growth suppression of breast cancer cells by FOXM1 inhibitors is accompanied by increased cell death and alterations in mitochondrial morphology and metabolic activity. Low doses of FOXM1 inhibitor strongly synergize with ferroptosis inducers to reduce cell viability, migration, colony formation, and expression of proliferation-related genes, and increase intracellular Fe<sup>+2</sup> and lipid peroxidation, markers of ferroptosis. Acquired resistance to FOXM1 inhibition is associated with increased expression of cancer stem-cell markers and proteins that repress ferroptosis, enabling cell survival and drug resistance. Notably, resistant cells are still sensitive to growth suppression by low doses of ferroptosis activators, effectively overcoming the acquired resistance.</p><p><strong>Conclusion: </strong>Delineating changes in viability and cell death pathways that can overcome drug resistance should be helpful in determining approaches that might best prevent or reverse resistance to therapeutic targeting of FOXM1 and ultimately improve patient clinical outcomes.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"307-320"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11455716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer. 美国引入 CDK4/6 抑制剂前后 HR+ 转移性乳腺癌患者的生存趋势:对 HER2- 和 HER2+ 转移性乳腺癌患者的 SEER 登记分析。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-08-23 DOI: 10.1007/s10549-024-07469-6
Adam Brufsky, Marilyn L Kwan, Rickard Sandin, Stella Stergiopoulos, Siddharth Karanth, Ashley S Cha-Silva, Doris Makari, Ravi K Goyal

Purpose: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have improved patient survival in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) in clinical trials and real-world studies. However, investigations of survival gains in broader HR+/HER2- mBC populations using epidemiological approaches are limited.

Methods: This retrospective study used SEER registry data to assess breast cancer-specific survival (BCSS) in patients diagnosed with HR+/HER2- de novo mBC from 2010 to 2019. Kaplan-Meier and Cox proportional hazards models were used to compare BCSS in patients diagnosed before (2010‒2013 with follow-up to 2014) and after (2015‒2018 with follow-up to 2019) the 2015 guideline recommendations for CDK4/6i use. A comparison was made to patients with HR+/HER2-positive (HER2+) de novo mBC, for which no major guideline changes occurred during 2015-2018.

Results: Data from 11,467 women with HR+/HER2- mBC and 3260 women with HR+/HER2+ mBC were included. After baseline characteristic adjustment, patients with HR+/HER2- mBC diagnosed post-2015 (n = 6163), had an approximately 10% reduction in risk of BC-specific death compared with patients diagnosed pre-2015 (n = 5304; HR = 0.895, p < 0.0001). Conversely, no significant change was observed in HR+/HER2+ BCSS post-2015 (n = 1798) versus pre-2015 (n = 1462). Similar results were found in patients aged ≥ 65 years.

Conclusion: Using one of the largest US population-based longitudinal cancer databases, significant improvements in BCSS were noted in patients with HR+/HER2- mBC post-2015 versus pre-2015, potentially due to the introduction of CDK4/6i post-2015. No significant improvement in BCSS was observed in patients with HR+/HER2+ mBC post-2015 versus pre-2015, likely due to the availability of HER2-directed therapies in both time periods.

目的:在临床试验和实际研究中,细胞周期蛋白依赖性激酶4/6抑制剂(CDK4/6i)改善了激素受体阳性/人表皮生长因子受体2阴性(HR+/HER2-)转移性乳腺癌(mBC)患者的生存率。然而,利用流行病学方法对更广泛的HR+/HER2- mBC人群的生存率提高情况进行的调查还很有限:这项回顾性研究利用SEER登记数据评估了2010年至2019年确诊为HR+/HER2-新发mBC患者的乳腺癌特异性生存率(BCSS)。研究使用卡普兰-梅耶尔模型和考克斯比例危险模型比较了2015年指南建议使用CDK4/6i之前(2010-2013年,随访至2014年)和之后(2015-2018年,随访至2019年)确诊患者的BCSS。与HR+/HER2阳性(HER2+)新发型mBC患者进行了比较,2015-2018年期间该指南未发生重大变化:纳入了11467名HR+/HER2- mBC女性患者和3260名HR+/HER2+ mBC女性患者的数据。经过基线特征调整后,2015年后确诊的HR+/HER2- mBC患者(n = 6163)与2015年之前确诊的患者(n = 5304; HR = 0.895, p 结论:与2015年之前确诊的患者相比,HR+/HER2- mBC患者的BC特异性死亡风险降低了约10%:利用美国最大的人口纵向癌症数据库之一,发现2015年后与2015年之前相比,HR+/HER2- mBC患者的BCSS显著改善,这可能是由于2015年后引入了CDK4/6i。2015年后与2015年之前相比,HR+/HER2+ mBC患者的BCSS没有明显改善,这可能是由于这两个时期都有HER2导向疗法。
{"title":"Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer.","authors":"Adam Brufsky, Marilyn L Kwan, Rickard Sandin, Stella Stergiopoulos, Siddharth Karanth, Ashley S Cha-Silva, Doris Makari, Ravi K Goyal","doi":"10.1007/s10549-024-07469-6","DOIUrl":"10.1007/s10549-024-07469-6","url":null,"abstract":"<p><strong>Purpose: </strong>Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have improved patient survival in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) in clinical trials and real-world studies. However, investigations of survival gains in broader HR+/HER2- mBC populations using epidemiological approaches are limited.</p><p><strong>Methods: </strong>This retrospective study used SEER registry data to assess breast cancer-specific survival (BCSS) in patients diagnosed with HR+/HER2- de novo mBC from 2010 to 2019. Kaplan-Meier and Cox proportional hazards models were used to compare BCSS in patients diagnosed before (2010‒2013 with follow-up to 2014) and after (2015‒2018 with follow-up to 2019) the 2015 guideline recommendations for CDK4/6i use. A comparison was made to patients with HR+/HER2-positive (HER2+) de novo mBC, for which no major guideline changes occurred during 2015-2018.</p><p><strong>Results: </strong>Data from 11,467 women with HR+/HER2- mBC and 3260 women with HR+/HER2+ mBC were included. After baseline characteristic adjustment, patients with HR+/HER2- mBC diagnosed post-2015 (n = 6163), had an approximately 10% reduction in risk of BC-specific death compared with patients diagnosed pre-2015 (n = 5304; HR = 0.895, p < 0.0001). Conversely, no significant change was observed in HR+/HER2+ BCSS post-2015 (n = 1798) versus pre-2015 (n = 1462). Similar results were found in patients aged ≥ 65 years.</p><p><strong>Conclusion: </strong>Using one of the largest US population-based longitudinal cancer databases, significant improvements in BCSS were noted in patients with HR+/HER2- mBC post-2015 versus pre-2015, potentially due to the introduction of CDK4/6i post-2015. No significant improvement in BCSS was observed in patients with HR+/HER2+ mBC post-2015 versus pre-2015, likely due to the availability of HER2-directed therapies in both time periods.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"223-235"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11455714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Male breast cancer: a multicenter study to provide a guide for proper management. 男性乳腺癌:一项多中心研究,为正确治疗提供指导。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-06-19 DOI: 10.1007/s10549-024-07380-0
Germana Lissidini, Luca Nicosia, Manuela Sargenti, Maria Cristina Cucchi, Alessandra Fabi, Giuseppe Falco, Marco Gardani, Greta Grilz, Ilaria Maugeri, Roberto Murgo, Alessandro Neri, Francesca Pellini, Cristiana Sensi, Serena Scomersi, Mario Taffurelli, Vincenzo Bagnardi, Chiara Oriecuia, Eleonora Pagan, Claudia Sangalli, Massimo Dessena, Paolo Veronesi, Viviana Galimberti

Introduction: To offer an extensive retrospective experience on the management of male breast cancer.

Methods: A multicenter retrospective observational cohort study was conducted, including male patients diagnosed with breast cancer (invasive or in situ) in 12 Italian breast units from January 1975 to December 2019. Patients aged 18 years or older were assessed for eligibility. Exclusion criteria were metastatic cancer at diagnosis, previous cancer(s), received neoadjuvant treatment, incomplete data on (neo) adjuvant treatment(s), and/or follow-up data. Data on radiological examinations, demographic characteristics, risk factors, histological features, receptor status, treatments, and follow-up were collected.

Results: In a series of 671 male patients with breast cancer assessed for eligibility, 403 (28 in situ and 375 invasive neoplasms) were included in the study. All included patients underwent surgery. The median age at surgery was 63.8 years (IQR 56.1-72.1). In 68% of cases, patients underwent echography, and in 55.1%, a mammography. Most patients were ER and PR positive (63.8%), HER2 negative (80.4%), with high (≥ 20%) Ki67 values (61.3%), and luminal B subtype (51.1%). The 10-year overall survival was 73.6% (95% CI 67.0-79.1) for invasive breast cancer and 90% (95% CI 65.6-97.4) for in situ breast cancer. In patients with invasive breast cancer, at univariable analysis, having a G3 tumor (vs. G1), pT2/3/4 (vs. pT1), pN2/3 (vs. pN0), luminal B subtype with Ki67 ≥ 20% (vs. Luminal A), were significantly associated with a higher risk of death. In multivariable analyses, pT2/3/4 (vs. pT1) remained significantly associated with a higher risk of death (HR 3.14, 95% CI 1.83-5.39), and having a HER2 positive or a triple-negative subtype (vs. Luminal A) was also significantly associated with a higher risk of mortality (HR 4.76, 95% CI 1.26-18.1).

Conclusion: Male breast cancer is a rare disease, the better understanding of which is necessary for a more effective diagnostic and therapeutic approach.

简介:目的提供男性乳腺癌治疗的广泛回顾性经验:开展了一项多中心回顾性观察队列研究,包括1975年1月至2019年12月期间在意大利12个乳腺科确诊为乳腺癌(浸润性或原位)的男性患者。年满 18 周岁的患者均接受了资格评估。排除标准为确诊时为转移性癌症、曾患癌症、接受过新辅助治疗、(新)辅助治疗数据不完整和/或随访数据不完整。研究人员收集了放射学检查、人口统计学特征、风险因素、组织学特征、受体状态、治疗和随访数据:在一系列经过资格评估的 671 名男性乳腺癌患者中,有 403 名(28 名原位癌患者和 375 名浸润性肿瘤患者)被纳入研究。所有患者均接受了手术治疗。手术时的中位年龄为 63.8 岁(IQR 56.1-72.1)。68%的患者接受了超声波检查,55.1%的患者接受了乳房X光检查。大多数患者ER和PR阳性(63.8%),HER2阴性(80.4%),Ki67值高(≥20%)(61.3%),管腔B亚型(51.1%)。浸润性乳腺癌患者的10年总生存率为73.6%(95% CI 67.0-79.1),原位乳腺癌患者的10年总生存率为90%(95% CI 65.6-97.4)。在浸润性乳腺癌患者中,在单变量分析中,G3肿瘤(与G1相比)、pT2/3/4(与pT1相比)、pN2/3(与pN0相比)、Ki67≥20%的管腔B亚型(与管腔A相比)与较高的死亡风险显著相关。在多变量分析中,pT2/3/4(vs.pT1)仍与较高的死亡风险显著相关(HR 3.14,95% CI 1.83-5.39),HER2阳性或三阴性亚型(vs.管腔A)也与较高的死亡风险显著相关(HR 4.76,95% CI 1.26-18.1):男性乳腺癌是一种罕见疾病,有必要对其有更深入的了解,以便采取更有效的诊断和治疗方法。
{"title":"Male breast cancer: a multicenter study to provide a guide for proper management.","authors":"Germana Lissidini, Luca Nicosia, Manuela Sargenti, Maria Cristina Cucchi, Alessandra Fabi, Giuseppe Falco, Marco Gardani, Greta Grilz, Ilaria Maugeri, Roberto Murgo, Alessandro Neri, Francesca Pellini, Cristiana Sensi, Serena Scomersi, Mario Taffurelli, Vincenzo Bagnardi, Chiara Oriecuia, Eleonora Pagan, Claudia Sangalli, Massimo Dessena, Paolo Veronesi, Viviana Galimberti","doi":"10.1007/s10549-024-07380-0","DOIUrl":"10.1007/s10549-024-07380-0","url":null,"abstract":"<p><strong>Introduction: </strong>To offer an extensive retrospective experience on the management of male breast cancer.</p><p><strong>Methods: </strong>A multicenter retrospective observational cohort study was conducted, including male patients diagnosed with breast cancer (invasive or in situ) in 12 Italian breast units from January 1975 to December 2019. Patients aged 18 years or older were assessed for eligibility. Exclusion criteria were metastatic cancer at diagnosis, previous cancer(s), received neoadjuvant treatment, incomplete data on (neo) adjuvant treatment(s), and/or follow-up data. Data on radiological examinations, demographic characteristics, risk factors, histological features, receptor status, treatments, and follow-up were collected.</p><p><strong>Results: </strong>In a series of 671 male patients with breast cancer assessed for eligibility, 403 (28 in situ and 375 invasive neoplasms) were included in the study. All included patients underwent surgery. The median age at surgery was 63.8 years (IQR 56.1-72.1). In 68% of cases, patients underwent echography, and in 55.1%, a mammography. Most patients were ER and PR positive (63.8%), HER2 negative (80.4%), with high (≥ 20%) Ki67 values (61.3%), and luminal B subtype (51.1%). The 10-year overall survival was 73.6% (95% CI 67.0-79.1) for invasive breast cancer and 90% (95% CI 65.6-97.4) for in situ breast cancer. In patients with invasive breast cancer, at univariable analysis, having a G3 tumor (vs. G1), pT2/3/4 (vs. pT1), pN2/3 (vs. pN0), luminal B subtype with Ki67 ≥ 20% (vs. Luminal A), were significantly associated with a higher risk of death. In multivariable analyses, pT2/3/4 (vs. pT1) remained significantly associated with a higher risk of death (HR 3.14, 95% CI 1.83-5.39), and having a HER2 positive or a triple-negative subtype (vs. Luminal A) was also significantly associated with a higher risk of mortality (HR 4.76, 95% CI 1.26-18.1).</p><p><strong>Conclusion: </strong>Male breast cancer is a rare disease, the better understanding of which is necessary for a more effective diagnostic and therapeutic approach.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"29-40"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141417775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interaction of base excision repair gene polymorphism and estrogen-DNA adducts in breast cancer risk among East Asian women. 碱基切除修复基因多态性与雌激素-DNA 加合物在东亚妇女乳腺癌风险中的相互作用。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-05 DOI: 10.1007/s10549-024-07418-3
Hsing-Wu Chen, Wen-Hung Kuo, Yen-Shen Lu, I-Chun Chen, Fu-Chang Hu, Ming-Yang Wang, Muhammad Zahid, Eleanor G Rogan, Ann-Lii Cheng, Ching-Hung Lin

Purpose: In East Asia, the incidence of breast cancer has been increasing rapidly, particularly among premenopausal women. An elevated ratio of estrogen-DNA adducts was linked to a higher risk of breast cancer. The present study explored the influence of the interaction between base excision repair (BER) gene polymorphisms and estrogen-DNA adducts on breast cancer risk.

Methods: We conducted a case-control study comprising healthy volunteers and individuals with benign breast disease (control arm, n = 176) and patients with invasive carcinoma or carcinoma in situ (case arm, n = 177). Genotyping for BER-related genes, including SMUG1, OGG1, ERCC5, and APEX1, was performed. A logistic regression model, incorporating interactions between gene polymorphisms, estrogen-DNA adduct ratio, and clinical variables, was used to identify the risk factors for breast cancer.

Results: Univariate analysis indicated marginal associations between breast cancer risk and APEX1 rs1130409 T > G (P = 0.057) and APEX1 rs1760944 T > G (P = 0.065). Multivariate regression analysis revealed significant associations with increased breast cancer risk for APEX1_rs1130409 (GT/GG versus TT) combined with a natural logarithmic value of the estrogen-DNA adduct ratio (estimated OR 1.164, P = 0.023) and premenopausal status with an estrogen-DNA adduct ratio > 2.93 (estimated OR 2.433, P = 0.001).

Conclusion: APEX1_rs1130409 (GT/GG versus TT) polymorphisms, which are related to decreased BER activity, combined with an increased ratio of estrogen-DNA adducts, increase the risk of breast cancer in East Asian women.

目的:在东亚,乳腺癌的发病率迅速上升,尤其是绝经前妇女。雌激素-DNA 加合物比值升高与乳腺癌风险升高有关。本研究探讨了碱基切除修复(BER)基因多态性与雌激素-DNA加合物之间的相互作用对乳腺癌风险的影响:我们进行了一项病例对照研究,研究对象包括健康志愿者和良性乳腺疾病患者(对照组,n = 176)以及浸润癌或原位癌患者(病例组,n = 177)。对 BER 相关基因(包括 SMUG1、OGG1、ERCC5 和 APEX1)进行了基因分型。采用逻辑回归模型,结合基因多态性、雌激素-DNA加合物比值和临床变量之间的相互作用,确定乳腺癌的风险因素:单变量分析表明,乳腺癌风险与APEX1 rs1130409 T > G(P = 0.057)和APEX1 rs1760944 T > G(P = 0.065)之间存在边际关联。多变量回归分析显示,APEX1_rs1130409(GT/GG 与 TT)与雌激素-DNA 加合物比值的自然对数值(估计 OR 1.164,P = 0.023)以及绝经前状态与雌激素-DNA 加合物比值 > 2.93(估计 OR 2.433,P = 0.001)均与乳腺癌风险增加有显著关联:结论:APEX1_rs1130409(GT/GG 与 TT)多态性与 BER 活性降低有关,再加上雌激素-DNA 加合物比率升高,会增加东亚女性罹患乳腺癌的风险。
{"title":"Interaction of base excision repair gene polymorphism and estrogen-DNA adducts in breast cancer risk among East Asian women.","authors":"Hsing-Wu Chen, Wen-Hung Kuo, Yen-Shen Lu, I-Chun Chen, Fu-Chang Hu, Ming-Yang Wang, Muhammad Zahid, Eleanor G Rogan, Ann-Lii Cheng, Ching-Hung Lin","doi":"10.1007/s10549-024-07418-3","DOIUrl":"10.1007/s10549-024-07418-3","url":null,"abstract":"<p><strong>Purpose: </strong>In East Asia, the incidence of breast cancer has been increasing rapidly, particularly among premenopausal women. An elevated ratio of estrogen-DNA adducts was linked to a higher risk of breast cancer. The present study explored the influence of the interaction between base excision repair (BER) gene polymorphisms and estrogen-DNA adducts on breast cancer risk.</p><p><strong>Methods: </strong>We conducted a case-control study comprising healthy volunteers and individuals with benign breast disease (control arm, n = 176) and patients with invasive carcinoma or carcinoma in situ (case arm, n = 177). Genotyping for BER-related genes, including SMUG1, OGG1, ERCC5, and APEX1, was performed. A logistic regression model, incorporating interactions between gene polymorphisms, estrogen-DNA adduct ratio, and clinical variables, was used to identify the risk factors for breast cancer.</p><p><strong>Results: </strong>Univariate analysis indicated marginal associations between breast cancer risk and APEX1 rs1130409 T > G (P = 0.057) and APEX1 rs1760944 T > G (P = 0.065). Multivariate regression analysis revealed significant associations with increased breast cancer risk for APEX1_rs1130409 (GT/GG versus TT) combined with a natural logarithmic value of the estrogen-DNA adduct ratio (estimated OR 1.164, P = 0.023) and premenopausal status with an estrogen-DNA adduct ratio > 2.93 (estimated OR 2.433, P = 0.001).</p><p><strong>Conclusion: </strong>APEX1_rs1130409 (GT/GG versus TT) polymorphisms, which are related to decreased BER activity, combined with an increased ratio of estrogen-DNA adducts, increase the risk of breast cancer in East Asian women.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"283-292"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141537576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Breast Cancer Research and Treatment
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1